Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Considerations for Later Lines of Therapy in HCC Treatment

March 18th 2021

Experts in the field of HCC consider second and third lines of therapy after a patient’s disease state progresses after frontline atezolizumab-bevacizumab.

Personal Experience Using Atezolizumab-Bevacizumab in HCC Treatment

March 18th 2021

Laura M. Kulik, MD, leads a discussion about personal experiences using atezolizumab-bevacizumab and whether clinical trial data reflect real-world experience.

FDA Approves TheraSphere Y-90 Glass Microspheres for HCC

March 18th 2021

The FDA has approved TheraSphere™ Yttrium-90 Glass Microspheres for the treatment of patients with hepatocellular carcinoma.

As FDA Review Approaches, Finn Reflects on the Utility of Pembrolizumab, Nivolumab in HCC

March 17th 2021

Richard S. Finn, MD, discusses the data with pembrolizumab and nivolumab that support their utility in hepatocellular carcinoma.

Drawing Actionable Information From the Blood in Advanced Biliary Tract Cancer

March 17th 2021

A major barrier to routine genomic profiling of tumors in patients with biliary tract cancer is the lack of adequate tumor tissue in the biopsy samples; the analysis of circulating tumor DNA present in the plasma, is emerging as a promising alternative.

Emerging Combinations of TACE for BCLC Stage B/C HCC

March 17th 2021

Masatoshi Kudo, MD, PhD, reviews data from the LEAP-012 and TACTICS trials for intermediate stage hepatocellular carcinoma.

Role of TACE in BCLC Stage B HCC

March 17th 2021

Amit Singal, MD, MS, and Masatoshi Kudo, MD, PhD, comment on the role of TACE (transarterial chemoembolization) in early line settings for the management of BCLC (Barcelona Clinic Liver Cancer) stage B hepatocellular carcinoma and whether systemic therapy has the potential to replace TACE.

Dr. Finn on Treatment Considerations for HCC

March 16th 2021

Richard S. Finn, MD, discusses treatment considerations for patients with hepatocellular carcinoma.

Dr. Eng on the Potential of Trastuzumab Deruxtecan in HER2+ mCRC

March 16th 2021

Cathy Eng, MD, FACP, FASCO, discusses the potential of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive metastatic colorectal cancer.

Bintrafusp Alfa Monotherapy Showcases Efficacy, Durability in Second-Line Biliary Tract Cancer

March 16th 2021

Single-agent bintrafusp alfa demonstrated efficacy, durability, and an acceptable toxicity profile when used in patients with locally advanced or metastatic biliary tract cancer who have progressed on or are intolerant of frontline platinum-based chemotherapy.

Dr. Pillai on Sequential Treatment in HCC

March 16th 2021

Anjana Pillai, MD, discusses sequential treatment in hepatocellular carcinoma.

Dr. Kazmi on Emerging Biomarkers in CRC

March 15th 2021

Syed Kazmi, MD, discusses emerging biomarkers that could help guide treatment decisions in patients with colorectal cancer.

Liver Transplantation for Advanced Cholangiocarcinoma

March 15th 2021

Scenarios for which liver transplantation may be appropriate in advanced cholangiocarcinoma.

Advanced Cholangiocarcinoma: Criteria for Resection

March 15th 2021

Panelists discuss types of scans and other testing results that can be used to help identify patients with an advanced bile duct cancer who are eligible for surgical resection.

Dr. Heimbach on Liver Transplant Criteria in HCC

March 13th 2021

Julie K. Heimbach, MD, discusses the criteria for liver transplantation in patients with hepatocellular carcinoma.

Dr. Philip on Non-Operative Treatment Advances in CRC

March 12th 2021

Tony Philip, MD, discusses advances made in the treatment of patients with colorectal cancer.

GI Cancer Expert Is Searching for Big Leaps in Care

March 12th 2021

John L. Marshall, MD, has made it his mission to improve the lives of patients with GI cancers through innovative research, personalized medicine, and focused advocacy.

Comprehensive Genomic Testing Alters the Rapidly Evolving Cholangiocarcinoma Treatment Landscape

March 12th 2021

Daniel Lin, MD, MS, discusses pivotal trials examining important targeted agents for patients with cholangiocarcinoma and the importance of comprehensive genomic testing to guide treatment decisions.

FDA Will Reassess 6 Immunotherapy Accelerated Approvals

March 12th 2021

Six indications for immune checkpoint inhibitors granted under the FDA’s accelerated approval process that later failed confirmatory clinical trials are being reassessed as the agency continues an industry-wide evaluation of the pathway.

A New Standard of Care for Liver Cancer Treatment

March 11th 2021

A discussion about the recent data from trials that looked at atezolizumab-bevacizumab for the treatment of advanced HCC, and its role as the new standard of care.